Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sung Chul | - |
dc.contributor.author | Chun, Hoon Jai | - |
dc.date.accessioned | 2021-09-05T23:47:33Z | - |
dc.date.available | 2021-09-05T23:47:33Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-07-15 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/102704 | - |
dc.description.abstract | No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.subject | RANDOMIZED PHASE-III | - |
dc.subject | ADJUVANT CHEMOTHERAPY | - |
dc.subject | GASTROESOPHAGEAL ADENOCARCINOMA | - |
dc.subject | PERIOPERATIVE CHEMOTHERAPY | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | PLUS CISPLATIN | - |
dc.subject | TRIAL | - |
dc.subject | SURGERY | - |
dc.subject | CAPECITABINE | - |
dc.title | Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chun, Hoon Jai | - |
dc.identifier.doi | 10.5009/gnl.2013.7.4.385 | - |
dc.identifier.scopusid | 2-s2.0-84880315269 | - |
dc.identifier.wosid | 000322057500001 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.7, no.4, pp.385 - 393 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 7 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 385 | - |
dc.citation.endPage | 393 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001789253 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-III | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | GASTROESOPHAGEAL ADENOCARCINOMA | - |
dc.subject.keywordPlus | PERIOPERATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | PLUS CISPLATIN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordAuthor | Stomach neoplasms | - |
dc.subject.keywordAuthor | Drug therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.